Schwab Charles Investment Management Inc. lifted its position in shares of Alkermes PLC (NASDAQ:ALKS) by 4.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 469,803 shares of the company’s stock after acquiring an additional 20,999 shares during the period. Schwab Charles Investment Management Inc. owned 0.31% of Alkermes worth $23,885,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in ALKS. Greenwood Capital Associates LLC lifted its holdings in Alkermes by 1.1% in the second quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock worth $219,000 after purchasing an additional 41 shares during the period. M&T Bank Corp lifted its holdings in Alkermes by 2.9% in the second quarter. M&T Bank Corp now owns 7,135 shares of the company’s stock worth $413,000 after purchasing an additional 200 shares during the period. Toronto Dominion Bank lifted its holdings in Alkermes by 12.7% in the second quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock worth $109,000 after purchasing an additional 212 shares during the period. Teachers Retirement System of The State of Kentucky lifted its holdings in Alkermes by 0.4% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 78,620 shares of the company’s stock worth $4,558,000 after purchasing an additional 292 shares during the period. Finally, People s United Financial Inc. lifted its holdings in Alkermes by 3.3% in the second quarter. People s United Financial Inc. now owns 9,389 shares of the company’s stock worth $544,000 after purchasing an additional 297 shares during the period. Institutional investors and hedge funds own 99.69% of the company’s stock.

Shares of Alkermes PLC (NASDAQ:ALKS) opened at $51.56 on Friday. Alkermes PLC has a 1-year low of $46.42 and a 1-year high of $63.40. The company has a quick ratio of 2.72, a current ratio of 3.05 and a debt-to-equity ratio of 0.23.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Thursday, October 26th. The company reported $0.03 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.04. Alkermes had a negative net margin of 20.12% and a negative return on equity of 7.27%. The company had revenue of $217.40 million during the quarter, compared to the consensus estimate of $231.29 million. During the same period in the prior year, the company earned ($0.09) EPS. Alkermes’s revenue was up 20.6% on a year-over-year basis. research analysts forecast that Alkermes PLC will post -0.59 EPS for the current fiscal year.

Several research firms recently weighed in on ALKS. Credit Suisse Group reduced their price objective on shares of Alkermes from $70.00 to $66.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Barclays set a $50.00 price objective on shares of Alkermes and gave the stock a “hold” rating in a report on Thursday, October 26th. Citigroup set a $62.00 price objective on shares of Alkermes and gave the stock a “hold” rating in a report on Thursday, October 26th. ValuEngine raised shares of Alkermes from a “sell” rating to a “hold” rating in a report on Friday, December 1st. Finally, Mizuho set a $81.00 price objective on shares of Alkermes and gave the stock a “buy” rating in a report on Saturday, October 21st. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the stock. Alkermes presently has a consensus rating of “Hold” and an average target price of $63.55.

In other Alkermes news, SVP Michael J. Landine sold 15,000 shares of the business’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $48.71, for a total transaction of $730,650.00. Following the sale, the senior vice president now owns 178,693 shares in the company, valued at approximately $8,704,136.03. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP James M. Frates sold 20,932 shares of the business’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $50.51, for a total value of $1,057,275.32. Following the sale, the senior vice president now owns 164,971 shares in the company, valued at approximately $8,332,685.21. The disclosure for this sale can be found here. Insiders sold a total of 109,364 shares of company stock valued at $5,355,310 over the last three months. 5.34% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Schwab Charles Investment Management Inc. Purchases 20,999 Shares of Alkermes PLC (ALKS)” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/schwab-charles-investment-management-inc-purchases-20999-shares-of-alkermes-plc-alks/1764805.html.

About Alkermes

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.